Skip to content

Septerna, Inc. SEPN Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Amgen logo
AmgenAMGN
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Arrowhead Research logo
Arrowhead ResearchARWR
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s accrued liabilities, current?
Septerna, Inc. (SEPN) reported accrued liabilities, current of $8.63M in Q1 2026.
How has Septerna, Inc.'s accrued liabilities, current changed year-over-year?
Septerna, Inc.'s accrued liabilities, current increased by 98.3% year-over-year, from $4.35M to $8.63M.
What is the long-term trend for Septerna, Inc.'s accrued liabilities, current?
Over 2 years (2023 to 2025), Septerna, Inc.'s accrued liabilities, current has grown at a 68.7% compound annual growth rate (CAGR), from $4.28M to $12.17M.